KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Acquisitions (2016 - 2024)

Charles River Laboratories International (CRL) has 14 years of Acquisitions data on record, last reported at $5.5 million in Q2 2024.

  • For Q2 2024, Acquisitions changed N/A year-over-year to $5.5 million; the TTM value through Sep 2025 reached $5.5 million, down 96.35%, while the annual FY2024 figure was $5.5 million, 97.19% down from the prior year.
  • Acquisitions reached $5.5 million in Q2 2024 per CRL's latest filing, down from $144.6 million in the prior quarter.
  • Across five years, Acquisitions topped out at $906.3 million in Q2 2021 and bottomed at -$518000.0 in Q4 2020.
  • Average Acquisitions over 5 years is $199.6 million, with a median of $94.2 million recorded in 2021.
  • The widest YoY moves for Acquisitions: up 38550.15% in 2020, down 1059.26% in 2020.
  • A 5-year view of Acquisitions shows it stood at -$518000.0 in 2020, then soared by 293.44% to $1.0 million in 2021, then surged by 28182.63% to $283.4 million in 2022, then crashed by 48.97% to $144.6 million in 2023, then plummeted by 96.21% to $5.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Acquisitions were $5.5 million in Q2 2024, $144.6 million in Q4 2023, and $50.2 million in Q2 2023.